<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05628311</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI362A301</org_study_id>
    <nct_id>NCT05628311</nct_id>
  </id_info>
  <brief_title>A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study (DREAMS-1) to Evaluate the Efficacy and Safety of IBI362 in Chinese Type 2 Diabetes Patients With Poor Glycemia Control Only Through Diet and Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study&#xD;
      to evaluate the effectiveness and safety of IBI362 in patients with type 2 diabetes (T2D)&#xD;
      with poor glycemia control only through diet and exercise. This study plans to enroll about&#xD;
      300 T2D subjects who still fail to meet the HbA1c standard after at least 2 months of simple&#xD;
      diet and exercise control. During the whole study, subjects will be required to maintain diet&#xD;
      and exercise control.&#xD;
&#xD;
      The whole trial period includes a 2-week screening period, a 6-week introduction period, a 24&#xD;
      week double-blind treatment period, a 24 week study extension period and a 4-week safety&#xD;
      follow-up period.&#xD;
&#xD;
      Subjects who met the randomization criteria will be randomly assigned to the IBI362 4.0 mg&#xD;
      group, the IBI362 6.0 mg group and the placebo group at 1:1:1. The randomization&#xD;
      stratification factors were (V3) HbA1c&lt;8.5% or HbA1c ≥ 8.5% before randomization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2022</start_date>
  <completion_date type="Anticipated">January 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 8, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c change from baseline at week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with HbA1c&lt;7.0% at week 24</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, Incidence and severity of adverse events and correlation with study drug;</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak plasma concentration (Tmax)</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak plasma concentration (Cmax)</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under curve (AUC)</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volume distribution (V)</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life (half-life, T1/2)</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clearance rate (clearance, CL)</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in PD parameters fasting insulin at different time points before and after administration.</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in PD parameters fasting C-peptide at different time points before and after administration.</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>IBI362 4.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>①2mg, subcutaneously (SC), once a week* 4weeks;&#xD;
②4mg, SC, once a week* 44weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI362 6.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>①2mg, SC, once a week* 4weeks;&#xD;
②4mg, SC, once a week* 4weeks；&#xD;
③6mg, SC, once a week* 40weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, SC, once a week* 24weeks;&#xD;
2mg, SC, once a week* 4weeks;&#xD;
4mg, SC, once a week* 4weeks；&#xD;
6mg, SC, once a week* 16weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo administered subcutaneously (SC) once a week.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI362</intervention_name>
    <description>IBI362 administered subcutaneously (SC) once a week.</description>
    <arm_group_label>IBI362 4.0 mg</arm_group_label>
    <arm_group_label>IBI362 6.0 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. T2D was diagnosed according to WHO standards in 1999 for at least 2 months&#xD;
&#xD;
          2. Age ≥ 18 when signing the informed consent form&#xD;
&#xD;
          3. The blood glucose was not well controlled after simple diet and exercise within 2&#xD;
             months before screening, and the local laboratory tested 7.5% ≤ HbA1c ≤ 10.5% during&#xD;
             screening&#xD;
&#xD;
          4. Maintain a stable diet and exercise lifestyle during the study&#xD;
&#xD;
          5. Subjects voluntarily signed the informed consent form and agreed to strictly follow&#xD;
             the requirements of this protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who the investigator thinks may be allergic to the components in the study&#xD;
             drug or similar drugs&#xD;
&#xD;
          2. Weight change&gt;5% within 12 weeks before screening (chief complaint)&#xD;
&#xD;
          3. Used any oral hypoglycemic drugs within 2 months before screening; ≥ 3 oral&#xD;
             hypoglycemic drugs have been used together more than 2 months before screening&#xD;
&#xD;
          4. Previous diagnosis of type 1 diabetes (including adult latent autoimmune diabetes),&#xD;
             special type diabetes or gestational diabetes&#xD;
&#xD;
          5. There are active or untreated malignant tumors within 5 years before screening, or&#xD;
             patients are in remission of clinical malignant tumors (except patients with skin&#xD;
             basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate&#xD;
             carcinoma in situ or papillary thyroid carcinoma who have no recurrence after surgery)&#xD;
&#xD;
          6. Mental illness existed in the past or at the time of screening, and the researcher&#xD;
             thinks it is not suitable to participate in this study&#xD;
&#xD;
          7. Pregnant or lactating women, or men or women who are fertile and unwilling to use&#xD;
             contraception throughout the study period&#xD;
&#xD;
          8. The investigator believes that the subject has any other factors that may affect the&#xD;
             efficacy or safety evaluation of this study and is not suitable to participate in this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qingjiang Ni</last_name>
    <phone>0512-69566088</phone>
    <email>qingjiang.ni@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalong Zhu</last_name>
      <phone>+86-025-68182432</phone>
      <email>zhudalong@nju.edc.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jiajun Zhao</last_name>
      <phone>+86-15168889899</phone>
      <email>jjzhao@sdu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 17, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2022</study_first_posted>
  <last_update_submitted>January 27, 2023</last_update_submitted>
  <last_update_submitted_qc>January 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

